January 14, 2020
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments.
The pharmaceutical company has now acquired the full license for Proteus’ mental health...
August 30, 2018
Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health. Announced this morning by the pharmaceutical company, the rollout will initially be limited to give Otsuka and Magellan a better idea of how best to deploy the technology at scale.
“We are eager for...
July 6, 2012
Proteus Biomedical's Raisin system
Intelligent medicine platform developer Proteus Biomedical has changed its name to Proteus Digital Health, to "better reflect" what the company does, Chief Product Officer David O'Reilly told MobiHealthNews in an email this week. Proteus also inked a deal with Japan-based Otsuka Pharmaceutical, which is known for its Abilify drug for schizophrenia and bipolar...